SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

Search

Laboratorios Farmaceuticos Rovi SA

Aperta

SettoreSettore sanitario

73.85 1.79

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.6

Massimo

74.25

Metriche Chiave

By Trading Economics

Entrata

49M

76M

Vendite

51M

210M

P/E

Media del settore

30.932

84.243

EPS

1.135

Rendimento da dividendi

1.28

Margine di Profitto

35.965

Dipendenti

2,197

EBITDA

49M

84M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+23.54% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.28%

2.28%

Utili prossimi

25 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

499M

3.7B

Apertura precedente

72.06

Chiusura precedente

73.85

Notizie sul Sentiment di mercato

By Acuity

50%

50%

151 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 feb 2026, 00:00 UTC

Azioni calde

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb 2026, 22:55 UTC

Utili

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb 2026, 21:44 UTC

Utili

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb 2026, 21:39 UTC

Utili

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb 2026, 00:00 UTC

Utili

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb 2026, 00:00 UTC

Utili

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb 2026, 23:45 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb 2026, 23:32 UTC

Discorsi di Mercato

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb 2026, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb 2026, 22:30 UTC

Utili

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb 2026, 22:30 UTC

Utili

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb 2026, 22:21 UTC

Utili

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 22:17 UTC

Discorsi di Mercato

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb 2026, 22:15 UTC

Discorsi di Mercato

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb 2026, 22:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

4 feb 2026, 21:53 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb 2026, 21:51 UTC

Utili

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 feb 2026, 21:45 UTC

Utili

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb 2026, 21:44 UTC

Utili

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb 2026, 21:43 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb 2026, 21:41 UTC

Utili

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 21:36 UTC

Discorsi di Mercato

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb 2026, 21:30 UTC

Utili

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Utili

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Utili

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Confronto tra pari

Modifica del prezzo

Laboratorios Farmaceuticos Rovi SA Previsione

Obiettivo di Prezzo

By TipRanks

23.54% in crescita

Previsioni per 12 mesi

Media 90 EUR  23.54%

Alto 90 EUR

Basso 90 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Laboratorios Farmaceuticos Rovi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.1 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

151 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat